Refractory/recurrent primary central nervous system lymphoma (PCNSL)

Clinical trials for Refractory/recurrent primary central nervous system lymphoma (PCNSL) explained in plain language.

Never miss a new study

Get alerted when new Refractory/recurrent primary central nervous system lymphoma (PCNSL) trials appear

Sign up with your email to follow new studies for Refractory/recurrent primary central nervous system lymphoma (PCNSL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Completed 1

New drug combo shows promise for tough brain cancer

Disease control Completed

This study tested the safety and effectiveness of combining two targeted drugs, copanlisib and ibrutinib, in 18 adults with primary CNS lymphoma that had returned or not responded to prior therapy. The goal was to find the best dose and see how many patients' tumors shrank. This …

Matched conditions: REFRACTORY/RECURRENT PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)

Phase 1/2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control

Last updated Jun 27, 2026 09:03 UTC

Refractory/recurrent primary central nervous system lymphoma (PCNSL)

Get alerted when new Refractory/recurrent primary central nervous system lymphoma (PCNSL) trials appear

New drug combo shows promise for tough brain cancer